Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium SCHEMBL1842811 | 0.99 | ABL1 (0.38) | ABL1NPC1RAB9ASMN1; SMN2CREBBP | |
| SCHEMBL1842805 | 0.99 | ABL1 (0.38) | ABL1NPC1RAB9ASMN1; SMN2CREBBP | |
| Lithium Ion SCHEMBL1842806 | 0.92 | ABL1 (0.38) | ABL1NPC1RAB9ASMN1; SMN2CREBBP | |
| SCHEMBL1844060 | 0.89 | ABL1 (0.40) | ABL1NPC1RAB9ASMN1; SMN2FGFR1 | |
| SCHEMBL1842109 | 0.89 | MAPK1 (0.43) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1846100 | 0.86 | ABL1 (0.38) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1840804 | 0.84 | ABL1 (0.39) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1841588 | 0.83 | — | — | |
| SCHEMBL1841659 | 0.83 | NPC1 (0.43) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2183120 | 0.83 | SCD (0.38) | ABL1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009156966-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-30 | — | — | WO | disclosed |